VIRIVirios Therapeutics, Inc.

Nasdaq virios.com


$ 0.19 $ -0.02 (-7.77 %)    

Friday, 02-Aug-2024 15:17:35 EDT
QQQ $ 448.50 $ -3.34 (-0.74 %)
DIA $ 397.31 $ -5.92 (-1.47 %)
SPY $ 532.92 $ -10.09 (-1.86 %)
TLT $ 98.17 $ 2.86 (3 %)
GLD $ 225.36 $ -0.41 (-0.18 %)
$ 0.206
$ 0.17
$ 0.22 x 200
-- x --
$ 0.17 - $ 0.19
$ 0.16 - $ 1.93
734,079
na
3.97M
$ 1.90
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 03-01-2024 12-31-2023 10-K
3 11-13-2023 09-30-2023 10-Q
4 08-11-2023 06-30-2023 10-Q
5 05-12-2023 03-31-2023 10-Q
6 03-14-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-12-2022 06-30-2022 10-Q
9 05-13-2022 03-31-2022 10-Q
10 03-18-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-13-2021 06-30-2021 10-Q
13 05-14-2021 03-31-2021 10-Q
14 03-23-2021 12-31-2020 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 maxim-group-initiates-coverage-on-virios-therapeutics-with-buy-rating-announces-price-target-of-1

Maxim Group analyst Jason McCarthy initiates coverage on Virios Therapeutics (NASDAQ:VIRI) with a Buy rating and announces P...

 virios-therapeutics-inc-to-offer-85m-shares-of-common-stock-at-020-per-share

- SEC Filing

 reported-earlier-virios-therapeutics-prices-17m-public-offering-of-85m-common-stock-to-commence-preparations-for-planned-imc-2-long-covid-phase-2b-study-at-020share

Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company" or "Virios Therapeutics"), a development-stage biotechno...

 virios-therapeutics-announces-21m-proposed-public-offering-of-common-stock

Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company" or "Virios Therapeutics"), a development-stage biotechno...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION